Scribe Therapeutics raised about $129 million in a CRISPR-focused IPO, beginning trading on Nasdaq under the ticker SCTX after an upsized offering. The company’s early pipeline centers on in vivo gene editing programs for cardiovascular and metabolic disease targets, including a PCSK9-silencing approach entering Phase 1.